This study indicated that fully human anti-BCMA CAR-T (HRC0202) is a promising treatment for R/R MM patients who relapsed or refractory from prior anti-BCMA CAR-T infusion. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.